Prevention of Severe Postpartum Hypertension

Furosemide for Prevention of Severe Postpartum Hypertension: a Randomized Controlled Trial

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02450773

Enrollment

Registered

2015-05-21

Start date

2015-08-31

Completion date

2022-05-31

Last updated

2023-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

postpartum, preeclampsia, gestational hypertension

Brief summary

The purpose of this study is to determine whether postpartum administration of furosemide to women with antepartum hypertensive disorders (gestational hypertension, preeclampsia) or elevated blood pressure in the first 24 hours following delivery reduces severe postpartum hypertension.

Interventions

DRUGFurosemide

40 mg furosemide on postpartum day 1-6

DRUGPotassium chloride

20 meq potassium chloride on postpartum day 1-6

DRUGPlacebo #1

Placebo (for furosemide)

DRUGPlacebo #2

Placebo (for KCl)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Yes

Inclusion criteria

Women \> 18 years of age or emancipated minors Women undergoing vaginal or cesarean delivery at \> 23 weeks gestation with: * Antepartum diagnosis of gestational hypertension * Antepartum diagnosis of preeclampsia * Antepartum diagnosis of preeclampsia with severe features * Mild hypertension (\<150/100) in first 24 hours following delivery

Exclusion criteria

* Chronic hypertension * Allergy to furosemide * Pre-existing hypokalemia (serum K \< 3.0 meq/L) * Chronic kidney disease * Serum Cr \> 1.1 * Inability to obtain informed consent * Pre-existing diuretic use * Oliguria

Design outcomes

Primary

Measure	Time frame	Description
Composite maternal morbidity	0-6 weeks following delivery	Requiring antihypertensive medication at discharge, readmission for blood pressure, end-organ damage from hypertension

Secondary

Measure	Time frame	Description
Adverse events associated with furosemide	0-6 weeks following delivery	Hypokalemia

Other

Measure	Time frame	Description
Cardiovascular changes following delivery	0-1 week following delivery	Maternal echocardiogram, renin, aldosterone, B-natriuretic peptide levels

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026